 Recombinant human interferon-gamma adjunct therapy Aspergillus infection patient chronic granulomatous disease hallmark chronic granulomatous disease CGD defective killing ingested microorganisms phagocytic cells Invasive aspergillosis CGD patients virulent mortality rate patient autosomal recessive CGD progressive pulmonary aspergillosis unresponsive conventional antifungal therapy recombinant human interferon-gamma rHuIFN-gamma dramatic improvement clinical symptoms sedimentation rate radiographic scans consistent improvement bactericidal function neutrophil oxidative capacity serum neopterin levels measure macrophage activation dose-dependent manner rHuIFN-gamma therapy levels improved clinical parameters patient treatment usefulness single-photon emission tomography SPECT gallium scan pulmonary inflammatory lesions presence fibrosis rHuIFN-gamma benefit CGD patients serious infections unresponsive conventional therapy